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the past 2 years. Seven patients were excluded due to non-engraft- 
ment (3), progressive disease necessitating regimen change (2), or 
early death (2). Of  the 12 children included in the study, ages 
ranged from 2 to 22 years (median=I0).  The  male:female 
ratio=7:5. Stenr cell source was PBSC in all cases. Donor type was 
unrelated in 5 cases and related in 7. Reasons for R I -HSCT were: 
ALL(3), NHL(1), ANLL(I),  neuroblastoma (2), SCA(1), 1[3-tha- 
lassemia (1), Sandhoff syndrome(l) and Hyper IgM syndrome (2). 
All patients received conditioning regimens consisting of fludarib- 
ine (30 mg/m2/d X 6), busulfan (1 mg/kg q6 hr IV x 8), and ATG 
(40 mg/kg/d x 4). Cyclosporin (3mg/kg/dose BID)was used as 
GVI tD prophylaxis. Acute GVHD (aGVHD) occurred among 7 
of the 12 patients (incidence=58%); 3 grade Ii, 3 grade IlI, and 1 
grade IV. As expected, aGVHD was more frequent among recipi- 
ents of unrelated transplants; all 5 unrelated RI -HSCT recipients 
developed aGVHD vs. only 2 out of 7 related transplants (p=0.05). 
Complete engraftment was defined as an ANC greater than 500 
and more tllan 75% donor T lymphocytes based on VNTR.  Eight 
patients attained complete ngraftment by 40 days post-transplant 
and 4 patients were much later than 40 days (+108, 127, and 203) 
or not at all (1 long-term stable chimera). Six of the 8 patients 
who engrafted before day 40 developed aGVHD compared to 
only 1 case of aGVHD among the late engrafters (p=0.3). Chronic 
GVHD (cGVHD) occurred among 6 of the 10 evaluable patients 
(incidence=60%); 5 of these occurred among the 6 early engrafters 
vs only 1 cGVHD case among the 3 late engrafters (p=0.24). Of 
the 8 early engrafters, 4 are deceased and 4 are alive with cGVH. 
Among the 4 late engrafters, all are alive; 1 has cGVHD and 1 has 
had progression of Sandhoff syndrome. Although the data did not 
reach statistical significance within this small sample size, the 
results do support an association between the rapidity of engraft- 
ment and the development of acute and chronic GVHD among 
recipients of RI-HSCT. Further studies are warranted to more 
fillly address this issue. 
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ANTI-THYMOCYTE GLOBULIN (ATG), LOW DOSE TBI AND FLUDARA- 
BINE (FLU) CONDITIONING FOR ALLOGENEIC TRANSPLANTATION 
Lrola, L.; Scigliallo, E.; Fl"uchtlmlJz, S.; GJ'ossk~'eutz, C. . 
Non-myeloablative allogeneic PBPC transplant using low dose 
TBI (200 cGy) plus FLU results in lnodest rejection rates. Acute 
and chronic GvHD do not differ substantially from fully ablative 
transplantation. Adding ATG to conditioning produces substan- 
tial host immunosuppression a d in-vivo graft T ceil depletion. 
Twenty-five pts, not eligible for conventional allogeneic SCT by 
virtue of age or co-morbidities, underwent non-myeloablative 
transplantation using ATG 15 mg/kg/day days-4 to- l ,  TBI 200 
cGy on a single fi'action on day -5, fludarabine 301ng/kg/day on 
days-4 to-2. Oral MMF 15 mg/kg/dose Q 12 hrs and CSA 6 
mg/kg/dose Q 12 hrs were started on day-5. Grafts were PBPC 
nmbilized with filgrastim 10 mcg/kg/day. Median age was 53 (30- 
66), diagnoses were 11-NHI,, 6-AML, 3-MM, 1-SAA, 1-PNH 
and 1-MDS. Median CD34+ and CD3+ contents were 
9.05x106/kg and 1.64x108/kg respectively. Three pts (2 with 
VUDs and 1 with a sib donor) received 1 Ag misuratched graft. 
The rest were fully matched. Five pts received VUD grafts. 
Twenty-two pts were evaluable for chimerism: 20 had >98% 
donor chimerism, one 85% and one 23%. Nine pts. relapsed. One 
pt rejected the graft at 180 days. Median hospital stay was 27 days. 
Complications were: GvHD in 6 pts (3 pts had GI-II GvHD of 
skin and liver and 3 pts had GI I I - IV GvHD of liver and gut). 
Three of the pts with GvHD had mismatched grafts. Transplant 
related toxicity was seen in 4 pts and infection in 5 pts. Median 
follow up was 153 days (17-774). CR was seen in 10 pts. Five pts 
remain in CR at 208 to 513 days. One pt relapsed with NHL  after 
a CR of 728 days. Four pts developed significant GvHD and died. 
Of the 25 pts, 16 died (6 relapsed disease, 4 GvHD, 3 infection 
and 3 transplant-related toxicity) and 9 are alive (5 in CR and 4 
with relapsed isease). The addition of ATG to low dose TBI and 
FLU was well tolerated and resulted in 100% donor engraftment. 
As in other series of non-myeloablative transplantation, a high 
rate of relapse was obsmwed. Donor engraftment maybe facilitated 
by the addition of ATG to low dose TBI and FLU conditioning. 
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THE ROLE OF DIGITAL PHOTOGRAPHY IN THE DOCUMENTATION OF 
SKIN GRAFT VERSUS HOST DISEASE 
Mavqz~ese~l, 3/1.; Chauvet, D.; DoJ~ob~e, T.; &lpeT~ata, ft.; Childs, R. 
Ste711 Cell Alloge~zeic Tralz.rplalltatio~z Sectiolz, Hematology Bra~zeh, 
NHLBI, NatioJml hzstitutes of Health, DHHS, Bethesda, MD. 
Graft vs host disease (GVHD) remains a serious and potentially 
life threatening complication of allogeneic stem cell transplanta- 
t ion(SCT). Because a significant proportion of complications 
occur in the first 3 months, patients historically have remained 
geographically attached to the transplant center for 100 days or 
more following SCT. Nonmyeloablative or low intensity allo- 
geneic transplants (NST) are generally well tolerated and associat- 
ed with less to.-dcity than coventional myeloablative transplants. As 
a consequence, patients are frequently sent home as early as 2 
months post-transplant with instructions to taper their GVHD 
prophylaxis, to augment a GVT effect. Transplant recipients are 
at risk for delayed onset GVHD during dais period of immuno- 
suppression withdrawal. Members of the transplant center often 
find themselves managing vague symptoms of acute GVHD com- 
municated over the telephone by primary care physicians or the 
patient hemselves. The diagnosis of liver and GI GVHD is readi- 
ly interpertable based on lab findings or clinical parameters such 
as quantity of diarrhea. In contrast, skin rashes may be variable in 
nature and more difficult to interpret in terms of etiology and 
severity. Inaccurate descriptions of skin changes can lead to erro- 
neous diaguosis of acute or chronic skin GVHD which could have 
a deleterious impact on patient outcome. Furthernmre, the incor- 
rect or over treatment of skin GVHD with immunosuppression 
such as corticosteroids and CSA may result in increased suscepti- 
bility to infectious complications and could potentially delay or 
negate a GWI" effect. This frequently occuring diagnostic dilem- 
ma, has led our intsitute to initiate a trial of monitor ing skin 
abnormalities through the use of digital photographs (DP), when 
significant distance limits the ability of patients to quickly reutrn 
to the transplant center. Patients with access to digital cameras 
and the internet, transmit photographs directly to our transplant 
physicians for timely diagnosis and treatment management. This
system provides a mechanism to diagnose and objectively assess 
acute and chronic skin GVHD allowing for both precise manage- 
nrent as well as a method to document response to therapy. Our 
experience suggests that the use of DP may aid in the diagnosis 
and treatment of skin GVHD, particularly in those patients who 
have been discharged home early after NST. 
HISTOCOM PATIBILITY/ALTERNATIVE STEM 
CELL SOURCES 
119 
DLA-HAPLOIDENTICAL STEM CELL ALLOGRAFTS AFTER ANTI-CD44 
THERAPY AND NONMYELOABLATIVE CONDITIONING IN A PRECLINI- 
CAL CANINE MODEL 
Ft~kz~da, T.; &orb, R.F.; Gooley, T.; ,%~tos, E.B.; S,md~naiev, B.M. 
CliJlieal Research Divisimz, b;red H~ttcbiJTso~z CaJzcev Research C'e~zte'~; 
Seattle, HZA. 
Background: YVe previously reported that engraftment across a 
dog leukocyte antigen (DLA) haplotype-mismatched barrier can 
be achieved after reduced-intensity conditioning with 450 cGy 
,total body irradiation (TBI) plus post-grafting mycophenolate 
mofetil (MMF) / cyclosporine (CSP) (for 35 days) when anti 
CD44 monoelonal antibody (MAh), $5, is added to the regimen 
pretransplant. Here, we studied the effect of anti-CD44 therapy in 
facilitating engraftment of DLA-haploidentical donor cells after 
nonmyeloablative conditioning with 200 cGy TBI  and prolonged 
postgrafting immunosuppression. Methods:  Thirty recipient dogs 
were administered MAb $5, at a dose of 0.2 mg/kgJday from days 
100 
-7 through -2, before 200 cGy TBI. Unmodified G-CSF-mobi- 
lized peripheral blood stem cells (PBSC) from DLA-haploidenti- 
cal donors were infused followed by iunnunosuppression with 
MMF (5-I0 mg/kg BID SQ for 28-101 days) and CSP (3- 
15mg/kg BID PO for 102 days). Two dogs received additional 
weekly methotrexate (0.4 mg/kg IV from days 42 through 105) 
and 2 dogs received escalating dose of donor lymphocyte infusions 
(DLI) fi'om their donors. Results: All dogs achieved prompt ini- 
tial engraftment with donor chimerism of PBMC ranging from 5- 
90% (median; 60%) 3 weeks after transplant. However, of 2l dogs 
evaluable for engraftment, 15 (71%) rejected their donor grafts 
after discontinnation r dose-reduction f MMF/CSP (5-16 weeks 
after transplant). Graft rejections occurred later in dogs given pro- 
longed immnnosuppression when compared to those treated with 
short courses (median time to rejection; 13.5 weeks vs. 7 weeks). 
Sustained allografts for more than 20 weeks were observed in 6 
dogs (29% of evaluable dogs). One of the 2 dogs given DLI 
achieved conversion to full donor chimerism after the third DLI 
dose (CD3+ cells infilsed; lxl07/kg) with subsequent graft versus- 
host disease requiring therapy. Conclusion: Initial engraftment of 
DLA-haploidentical PBSC can be achieved by anti-CD44 therapy 
and 200 cGy TBI with MMF/CSP. In some cases, sustained allo- 
grafts were achieved, however, half the dogs rejected their donor 
grafts after discontinuation or dose-reduction of MMF/CSP. 
Modification to current protocols will be needed to consistently 
achieve long-lasting engraftment. 
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FROM HLA 
DISPARATE DONORS RESULTS IN A VERY LOW RISK OF _>GRADE II 
ACUTE & CHRONIC GVHD: CD34 DOSE AND NON-TBI CONDITIONING 
PREDICT FOR SIGNIFICANTLY IMPROVED SURVIVAL 
Styczy~ski, if/; Billote, G.B.2; Ctse'aJzg, }7; Harrison,, L.:; I, VolozvT~ik, 
K.2; l, Kischhove*, C.2; Ga,z,ilz, ,7.2; B'radley, M.:; Del Toro, G.e; Gemge, 
D.2; ~,an de VeJ~, C.:; Cairo, 3J.S. e 1. AlecLical University Bydgoszcz, 
Bydgoszcz, Poland; 2. ChildreJ~ )Hospital of New York Presbyterian, 
New York, NIT. 
We and others have demonstrated that UCB has been success- 
fully used as an alternative source of hematopoietic stem cells for 
both malignant and non-malignant diseases (Cairo et al, Blood 
90:4665, 1997). We analyzed the results of 31 UCBT in 29 pts 
between 1997-2002. Age: median 9 (0.7-20) yrs; 17M:I2F; and 
reed wt 2i kg" (range 8-95). Dx: 23 malignant (9 ALL, 4 AML, 1 
CML, 3 EID, 3 NHL, 2 NBL, 1 HLH), and 6 non-malignant (1 
B-Thal, 1 WAS, 1 FEL, 1 SAA, 1 FA, 1 Krabbe dis). HLA typing 
was done by serology class i (A & B) and high resolution DNA 
typing class II (DRB1). Donor sources: 3 (6/6), 7 (5/6), 21 (4/6). 
Conditioning: TBI-based (15), chemotherapy-based (6) and 
reduced intensity chemotherapy (10). 28 received ATG/MoAb. 
GVHD prophylaxis: MNIF/FK506 (20), CsA+steroids+~VINiF (7) 
or CsA+Mtx (4). UCB median TNC 4.9x107/kg (1.1-16.9), medi- 
an CD34+ 2.8x105/kg (0.2-9.9). 84% smwived more than 30 days. 
Of those surviving 30 d: med time to ANC >0.5x10~TL 24 d (1- 
79); reed time to PLT >20xl0V/L 31 d (1 206); 81% had ANC 
>0.5xI0')/L by day +60; 67% had PLT ->20x10'TL by day +180. 
There was a 10% primary graft fiailure. 23 were evaluable for 
A/CGVHD. 35% developed _>grade II AGVHD, reed 29d (7-53), 
22% developed ->grade III AGVItD; 5.9% developed extensive 
CGVHD. The estimated 1-yr OS is 42%. 14 remain alive and dis 
free 1-62 mo. Factors predicting positive outcome by univariate 
analysis: number of CD34+ cells/kg (p=0.045), number of 
TNC/kg (p=0.072), non-TBI conditioning (p=0.027), standard 
risk vs poor risk (p-0.036), and sex (F) (p=0.015). By multivariate 
analysis: number of CD34+ cells/kg (p=0.035), non-TBI condi- 
tioning (p=0.026) and sex (F) (p=0.031). Patients who survived 
received more CD34+ eells/kg (3.I vs 2x105, p=0.045) and more 
TNC/kg (5.1 vs 3x107, p=0.11). HLA disparity did not predict for 
OS. In summary, this experience with HLA disparate UCBT con- 
tinues to demonstrate a very low incidence of ->grade II AGVHD 
and extensive CGVHD, and more importantly, in a multivariate 
analysis, non-TBI conditioning and higher CD34/kg dose are the 
most important predictors for significantly improved survival. 
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OPTIMAL SELECTIVE TYPING STRATEGIES FOR DONOR REGISTRIES 
Miiller, C.R. ZKRD Gee'man Ntl. BoTze 3/larrow Donor Regist(y, UlllJ, 
Ge~wla W. 
A reasonable measure for the quality of the composition of a 
registry is the fraction of patients finding at least one matching 
donor on the first search of the registry. This indicates to 
which extent he phenotype spectrum of population is covered 
by the registry. For a population Hardy-Weinberg Equilibri- 
um, this "population coverage" can be estimated using the size 
of the registry and the HLA haplotype frequencies. Due to lim- 
ited funds, many registries contain a majority of donors which 
are only typed for HLA-A and -B. We have designed an algo- 
rithm to select such donors for HLA-DRBl-typing by their 
HLA-A, B-phenotype so that after a defined number of typings 
performed the expected population coverage is maximized. 
This algorithm uses HLA haplotype frequencies to estimate 
absolute HLA-A, B, DR-phenotype frequencies as well as con- 
ditional distributions of HLA-DRB1 subtypes for each HLA-A, 
B-phenotype. Then, taking into account the current registry 
composition, a sequence of donors to be typed for IILA-DRB1 
can be established optimizing the chance of a patient o have an 
HLA-A, B, DRBl-matching donor instantly. A computer sinm- 
lation of this process revealed that our strategy can save initially 
up to 60% of typing costs over a random selection of HLA 
types and that the gain in efficiency will then remain between 
15% and 25% until over 80% of the donors are fully typed. 
Since HLA typing costs are the largest burden on the budget of 
most registries this strategy can have a substantial economic 
impact. 
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OUTCOME OF UNRELATED UMBILICAL CORD-BLOOD TRANSPLANTS 
(UCBT) IN PEDIATRIC PATIENTS: EXPERIENCE OF ONE CENTER 
Rodrigltez-Marino, S. I; Coqldllard, G.~; Scbmoldt, [7.3; Dachao, L. ", 
Racle77zaker, A.z; Kletzel, ~i. s i. Pathology, Childrel~'s Me~lmrial Hospi- 
tal, Chicago, IL; 2. Northzveste*v~ UTdversit~,, Cl, icago, IL; 3. CtailctreJ~'s 
Memorial Hospital Pediatrics, Chicago, IL. 
Unrelated UCBT have been used as an alternative source of 
stem cells in the treatment ofnon-malignant and malignant disor- 
ders. From 7/6/95 to 7/11/02 seventy-one children underwent 
UCBT at Childrens Memorial Hospital. Fifty three had malig- 
nant disorders and 18 non-malignant. Thirty-eight were male and 
33 females with a mean age at transplant of 6.5 years (range 0.6- 
20.5 years). The ablation regimen consisted of fFBI 1200cGy in 
150cGy fractions (days -8, -7, -6, -5), cyclophosphamide 60
mg/kg/day (days -4, -3, -2); and for patients with malignant disor- 
ders VP-16 was given at a lO00mg/m2/day as a CI (day 4). The 
GVHD prophylaxis consisted of CSA 5 mg/kg/day as a 24 hr CI, 
MTX 15/m2 on day 1 and 10rag/m2 on day +3 and +6 plus ATG 
40 lng/kg/day on days +l, +3, +5, and +7. Selection of UCB was 
made based on the HLA typing and total cell dose. HLA typing 
was originally performed by serological methods for class I and by 
DNA based methods for DRB1. Since March 2000, HLA typing 
has been performed using DNA-based typing methods only. 
Eighteen patients were HLA-A, B, and DR typed serologically 
only, and the degree of matching was 6/6 (n= I), 5/6 (n= 6), 4/6 
(n= 10) and 3/6 (n= 1). Fifty-three patients were DNA-typed, 
HLA-A and B at the group level and DRBI at the allele level. In 
these patients the degree of matching was: 6/6 (n=4), 5/6 (n=14), 
4/6 (n=33), and 3/6 (n=2). The total cell dose infused was a mean 
0.63 xl08/kg, (range 0.11- 1.92 xl08/kg). The time to achieve 
ANC> 500/UI were 27.4 (range 14-58 days) was achieved in 58 
pts. And for sustained platelets >20/UI 47days, (range 10-128 
days). And were achieved in 47pts. From the 71 patients, 35 died 
from infection (n= 11), relapse (n= 8), transplant related toxicity 
(n= 3), PTLD (n= 1), chronic GVHD (n= 1), and others (n- 9) 
from these 7 did not engraft. Forty seven patients developed 
AGVIID (grade I/]I n= 32 or grade III/IV n= 15), in 40 of them, 
AGVHD resolved with immune-suppressive th rapy. CGVHD in 
10 patients (resolved in 7, persisted in 3). The actuarial 3-year 
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